Sophrosyne logo

Latest News and Events from Sophrosyne

Stay up to date on our products and research.

AllPress ReleasesPublicationsCorporate InfoHere's to Us Series

Sophrosyne Pharmaceuticals Announces Dosing of First Subject in Multiple Ascending Dose Study for the Treatment of AUD

Jul 30, 2026|Press Releases

The Drinking Illusion

Jul 23, 2026|Here's to Us Series

Sophrosyne Corporate Deck

Jul 17, 2026|Corporate Info

Sophrosyne Pharmaceuticals Expands its Novel NCE Portfolio with Creation and Patent Filing of GLP-1 Combination

Jul 16, 2026|Press Releases

Sophrosyne Pharmaceuticals Appoints Renowned Hepatologist Dr. Ashwani Singal to its Scientific Advisory Board

Jul 13, 2026|Press Releases

Sophrosyne Pharmaceuticals Receives FDA Fast Track Designation for its Lead Product, SOPH-110S, for the Treatment of Alcohol Use Disorder (AUD)

Jun 18, 2026|Press Releases

Sophrosyne Pharmaceuticals Announces Dosing of First Subject in Phase I Study of Its Lead Asset for the Treatment of AUD

Apr 8, 2026|Press Releases

Sophrosyne Pharmaceuticals Invited to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 18, 2026|Press Releases

Sophrosyne Pharmaceuticals Announces Publication of Preclinical Findings for Its Lead Asset for Treatment of AUD

Jan 20, 2026|Press Releases

Alcohol related emergencies and deaths

Nov 19, 2025|Publications

Alcohol Treatment in the United States- NIAAA

Nov 19, 2025|Publications

Epidemiology of Recovery from Alcohol Use Disorder

Nov 19, 2025|Publications